Skip to main content

Riboflavin ophthalmic Pregnancy and Breastfeeding Warnings

Brand names: Photrexa, Photrexa Viscous

Medically reviewed by Drugs.com. Last updated on Mar 13, 2024.

Riboflavin ophthalmic Pregnancy Warnings

Use should be avoided.

US FDA pregnancy category: Not formally assigned to a pregnancy category.

Risk Summary: There are no data available on use of this drug in pregnant women to inform of a drug-related risk.

Animal development and reproductive studies have not been conducted. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Riboflavin ophthalmic Breastfeeding Warnings

Benefit should clearly outweigh risk.

Excreted into human milk: Data not available
Excreted into animal milk: Unknown

Comment: The effects in the nursing infant are unknown.

There are no data regarding the presence of this drug in human milk or its effect on milk production.

See references

See also

References for pregnancy information

  1. (2016) "Product Information. Photrexa (riboflavin ophthalmic)." Avedro, Inc.
  2. (2016) "Product Information. Photrexa Viscous (riboflavin ophthalmic)." Avedro, Inc.

References for breastfeeding information

  1. (2016) "Product Information. Photrexa (riboflavin ophthalmic)." Avedro, Inc.
  2. (2016) "Product Information. Photrexa Viscous (riboflavin ophthalmic)." Avedro, Inc.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer